The human myometrial CRH receptor: G proteins and second messengers.
The initiation of human parturition remains an enigma but is thought to involve a number of hormonal signals such as oxytocin and prostaglandins. One other possible signal is placentally derived corticotropin-releasing hormone (CRH). We have recently reported that the human myometrium expresses a specific receptor for CRH which changes to a high affinity state prior to term. In view of this we sought to determine whether this receptor is functionally linked to some of the known modulators of myometrial function. Myometrial membranes were prepared by differential centrifugation from either pregnant (caesarian section) or non-pregnant (hysterectomy) myometrium. For binding studies the membranes were incubated with radiolabelled oCRH at 22 degrees C for 2 h. For second messenger studies they were incubated at 37 degrees C for 10 or 30 min with either 0.5 mM ATP and 10 mM theophylline (cAMP) or 0.05 mM arachidonic acid or 0.5 mM linoleic acid (PGE2). When increasing concentrations of membranes were incubated with radiolabelled oCRH an interesting phenomenon was observed. In non-pregnant membranes the binding reached a plateau, whereas in membranes prepared from pregnant myometrium, the binding decreased at concentrations above 130 micrograms/ml. Possible explanations for this phenomenon include an inhibitor which prevents ligand-receptor binding or an enzyme which destroys the receptor binding region of the ligand. Incubation of both types of membranes with GTP or its analogue, GppNHp, resulted in a dose-dependent inhibition of specific binding suggesting that the myometrial CRH receptor is linked to a G regulatory protein.(ABSTRACT TRUNCATED AT 250 WORDS)
Grammatopoulos
D
D
Department of Clinical Biochemistry, University of Newcastle upon Tyne, The Medical School, UK.
Milton
N G
NG
Hillhouse
E W
EW
D000255:Adenosine Triphosphate / Q000494:pharmacology; D016718:Arachidonic Acid / Q000378:metabolism; D002462:Cell Membrane / Q000378:metabolism; D003346:Corticotropin-Releasing Hormone / Q000378:metabolism / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D015232:Dinoprostone / Q000378:metabolism; D005260:Female; D019204:GTP-Binding Proteins / Q000502:physiology*; D006160:Guanosine Triphosphate / Q000494:pharmacology; D006165:Guanylyl Imidodiphosphate / Q000494:pharmacology; D006801:Humans; D007743:Labor, Obstetric / Q000502:physiology; D019787:Linoleic Acid; D008041:Linoleic Acids / Q000378:metabolism; D009215:Myometrium / Q000378:metabolism*; D011247:Pregnancy; D018019:Receptors, Corticotropin-Releasing Hormone / Q000378:metabolism*; D015290:Second Messenger Systems / Q000502:physiology*; D013806:Theophylline / Q000494:pharmacology
D008041:Linoleic Acids; D018019:Receptors, Corticotropin-Releasing Hormone; D016718:Arachidonic Acid; D006165:Guanylyl Imidodiphosphate; D006160:Guanosine Triphosphate; D000255:Adenosine Triphosphate; D003346:Corticotropin-Releasing Hormone; D019787:Linoleic Acid; D013806:Theophylline; D000242:Cyclic AMP; D019204:GTP-Binding Proteins; D015232:Dinoprostone